Navigation Links
Tumor genome analysis unveils new insights into lung cancer
Date:11/4/2007

An international consortium of scientists today in an advanced online publication in the journal Nature revealed a comprehensive view of the altered genetic background of the type of lung cancer that is the most common cause of cancer deaths in humans.

Of particular interest was a specific proto-oncogene called NKX2-1 that appears involved in as many as 12 percent of lung adenocarcinomas the most common cause of cancer deaths worldwide, said the group, whose work was in part financed by the National Human Genome Research Institute (NHGRI). The group noted, however, that analysis indicates that many of the genes that play a role in the disease remain to be discovered.

This view of the lung cancer genome is unprecedented, both in its breadth and depth, said senior author Dr. Matthew Meyerson, a senior associate member of the Broad Institute of MIT and Harvard in Cambridge, Mass., and an associate professor at Dana-Farber Cancer Institute and Harvard Medical School in Boston. It lays an essential foundation, and has already pinpointed an important gene that controls the growth of lung cells. This information offers crucial inroads to the biology of lung cancer and will help shape new strategies for cancer diagnosis and therapy

The report is the first to emerge from the Tumor Sequencing Project that involves three genome centers: Baylor College of Medicine Human Genome Sequencing Center in Houston, The Broad Institute of Harvard and MIT in Cambridge, Mass., and Washington University in St. Louis, Mo.; and five cancer centers: Dana-Farber Cancer Institute in Boston, The University of Texas M. D. Anderson Cancer Center in Houston, Memorial Sloan-Kettering Cancer Center in New York, the University of Michigan and Washington University.

Each year, more than 1 million people worldwide die of lung cancer. In the United States, the annual death toll is 150,000. Lung adenocarcinoma, the topic of this study, is the most common cause of lung cancer.

This study illustrates the value in using high through-put sequencing and microarray analysis to understand the fundamental properties of tumors at the molecular level, said Dr. Richard Gibbs, director of the BCM Human Genome Sequencing Center, and one of the papers co-authors. The identification of this gene demonstrates the power of copy number analysis using arrays (or gene chips).

The authors wrote: This study represents a step toward comprehensive genomic characterization for one of the most common lung cancers, lung adenocarcinoma. Recent advances in massively parallel DNA sequencing technology may soon make it feasible to undertake similar comprehensive studies to identify all translocations, point mutations and epigenomic changes in cancer and thus point the way to an integrated picture of the cancer genome. Dr. Barbara A. Weir of Dana-Farber and the Broad Institute, Michele S. Woo of Dana-Farber and Gad Getz of the Broad Institute are first authors on the paper and contributed equally to the work.

The team found 57 frequent genomic changes in their analysis of the genetics of tumors taken from lung cancer patients. Of these, 15 are linked to genes known to be involved in lung cancer. The rest remain to be discovered.

The gene NKX2-1 is essential in the development of cells that line the alveoli of the lungs. Mice lacking the gene die at birth because they cannot breathe. However, it is a proto-oncogene, which means that it can mutate into a gene that promotes development of cancer.

Lung adenocarcinoma is the leading cause of cancer death worldwide. Using gene chip or microarrays, researchers compared the genomes of 371 lung adenocarcinomas to 242 normal lung samples using special gene chips to analyze approximately 250,000 genetic markers. Their analyses identified areas of genetic material that has been repeated or deleted in the tumors. Among these were six areas currently associated with known mutations in lung cancers.

The most common event was an increase in genetic information on one arm of chromosome 14, where NKX2-1 is found in that area of the chromosome. Using a variety of techniques, including RNA interference, they determined that NKX2-1 is essential for the survival of lung cancer cell lines that express the gene.


'/>"/>

Contact: Glenna Picton
picton@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Related biology news :

1. Mouse brain tumors mimic those in human genetic disorder
2. Researchers add new tool to tumor-treatment arsenal
3. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
4. Pulsating ultrasound enhances gene therapy for tumors
5. Scientists identify molecule that regulates well-known tumor suppressor
6. New tumor-suppressor gene discovered
7. NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses
8. Natural tumor suppressor in body discovered by UCSD medical researchers
9. Unexpected lock and key mechanism found for the assembly of tumor blood vessels
10. Double trouble: Cells with duplicate genomes can trigger tumors
11. Novel regulatory mechanism identified for key tumor suppressor p53
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):
(Date:2/28/2017)...  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company ... autoimmune diseases, asthma and allergic diseases and cancer, ... and full year ended December 31, 2016 and ... and clinical highlights. "During 2016, we ... by starting five clinical trials across our XmAb ...
(Date:2/28/2017)... ... February 28, 2017 , ... FireflySci is a small cuvette manufacturer ... late 2014, FFS had a mission to bring affordable and quality lab equipment to ... product that gives a lab everything needed to get started with using cuvettes. , ...
(Date:2/28/2017)... ... February 28, 2017 , ... ACEA Biosciences, a pioneer in cell analysis instrumentation ... Dr. Roger (Feng) Luo as the new Vice President of Global Clinical Development. ... drug companies, Dr. Luo will now team with Dr. Li Xu, Chief Medical Officer, ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen ... from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc. ... to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology ...
Breaking Biology Technology: